Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis
Titel:
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis
Auteur:
Ryerson, Lana Zhovtis Foley, John F Defer, Gilles Cohen, Jeffrey A Arnold, Douglas L Butzkueven, Helmut Cutter, Gary Giovannoni, Gavin Killestein, Joep Wiendl, Heinz Sinks, Susie Kuhelj, Robert Bodhinathan, Karthik Lasky, Tyler